Great work @nihanthy @tuttsakhil
Pleased to share our short commentary on the current adjuvant therapy landscape in RCC @nihanthy scivolve.com/casereports/25…
Excited to see our own, dynamic clinician and researcher, Dr Neeraj Agarwal running for ASCO nominating seat. Throwing our full weight behind him @batraatulonc @DrNikitaMehra @DrJasminPorwall @DharamKaushik5 @drshubhamsahni @RanjitKSMD @dr_rajapramanik @nihanthy @garg_h
Voting for the ASCO election is now open! I am honored to be running as one of the candidates for the @ASCO Nominating Committee seat. Visit asco.org/election to learn more about the candidates and place your vote! Thank you!!
More options in bladder cancer
Treatment after EVP in bladder cancer is undefined. Izalontamab brenitecan (HER2/3 TROP2 ADC) has good activity in bladder+lung cancer. A global randomised phase III has started enrolment 👉 Iza Bren alone vs platinum chemo in previously treated pts (including EVP). @OncoAlert
Breaking news from #ESMO25👉Improved OS in high risk biochemical recurrent #ProstateCancer on with ENZA+ADT vs ADT alone, HR: 0.59 (no OS benefit with ENZA monotherapy), 👏wonderful news for our pts👉congrats @SFreedlandMD @nealshore & the team. @OncoAlert @urotoday @PCF_Science
🎉 GU-ONCOCON 2025 was a tremendous success! Huge thanks to our keynote speakers: Prof. Neeraj Agrawal, Prof. Yüksel Ürün, Dr.Shilpa Gupta, Professor Yüksel Urun, Dr. Dharam Kaushik, and Dr. Ravindran Kanesvaran Their inspiring talks offered invaluable insights into GU oncology
Just came online in @TheLancet 👉Our two papers on improved OS with Enzalutamide + Talazoparib in mCRPC #ProstateCancer in all-comer & HRRm patients (Median OS and HRs👇). Weblinks to the papers👉 bit.ly/4lXkLtB and bit.ly/4nNIyOh @PCFnews @urotoday @OncoAlert
Just in👉Two @TheLancetOncol papers on patient-reported QOL results in ph3 TALAPRO-2 trial👉in all-comer & HRR deficient mCRPC #ProstateCancer pts👉Improved OS without compromising QOL👇Links: bit.ly/3DWHlSR & bit.ly/3E3SSQi @urotoday @OncoAlert @PCFnews 👇
On September 9, 2025, the Food and Drug Administration approved gemcitabine intravesical system (Inlexzo, Janssen Biotech, Inc.) for adults with BCG - unresponsive NMIBC with CIS with or without papillary tumors. Also known as TAR-200: this gemcitabine intravesical system is…
🎯 Announcing the Eurasia team for the Uromigos cup 🏆 November 7th and 8th - Nashville with Cristina Suarez. Current score is Eurasia =1 vs North America= 0 from the 🎯 darts competition!! @montypal & Americas got 51 ❤️ ‘likes’ in 10 days. Can Eurasia get more??
Excited to host @neerajaiims @shilpaonc @DharamKaushik5 @DrYukselUrun @ravikanesvaran at GUONCOCON2025 in Delhi… a true MDT meeting in urology cancers….also involves hands on robotic workshop in partial nephrectomy…. keep following and don’t forget to register …with…
Looking forward to hosting the second edition of our annual oncology meeting
United States 趨勢
- 1. Cheney 35.8K posts
- 2. #AcousticPianoSnowGlobe 1,902 posts
- 3. Nano Banana Pro 13.5K posts
- 4. First Take 42.4K posts
- 5. #NXXT_NEWS N/A
- 6. #TSTheErasTour 1,565 posts
- 7. Trump and Vance 27K posts
- 8. FINAL DRAFT FINAL LOVE 323K posts
- 9. #LoveDesignFinalEP 296K posts
- 10. Cam Newton 1,910 posts
- 11. SEDITIOUS BEHAVIOR 9,612 posts
- 12. Stephen A 35.3K posts
- 13. Husqvarna N/A
- 14. Bush 48.4K posts
- 15. Nnamdi Kanu 165K posts
- 16. Godzilla 21.3K posts
- 17. Haymitch 16.5K posts
- 18. #WeekndTourLeaks N/A
- 19. Pablo 66.5K posts
- 20. YOYOK N/A
Something went wrong.
Something went wrong.